Brookline Capital (NASDAQ:BCAC) announced in an 8-K this morning that its shareholders approved its combination with Apexigen at a special meeting July 27.
The filing did not include redemption figures, but the transaction also did not have a minimum cash condition beyond listing requirements. Brookline brought a $15 million PIPE alongside its trust in the deal and Lincoln Park also agreed to purchase up to $50 million of the combined entity’s stock in the two years following the transaction’s close.
Brookline traded below its estimated pro rata trust value of $10.22 throughout its July 25 redemption deadline, but has since soared to a close Wednesday at $10.75. Following the deal’s close, Apexigen is expected to trade on the Nasdaq under the symbol “APGN”.
The parties initially announced the $278 million combination on March 18. San Carlos, California-based Apexigen is developing a range of immunological cancer treatments with four currently in Phase II trials.
It announced the results of its Phase II trials to treat pancreatic cancer with its sotigalimab drug candidate in June.
ADVISORS
- Brookline Capital Markets is acting as capital markets advisor to Brookline Capital Acquisition Corp.
- Wedbush PacGrow is acting as exclusive strategic financial advisor to Apexigen.
- DLA Piper LLP (US) is serving as legal advisor to Brookline Capital Acquisition Corp.
- Wilson Sonsini Goodrich & Rosati, P.C. is serving as legal advisor to Apexigen.
Terms Tracker for the Week Ending April 18, 2025 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. Six new SPACs filed to IPO this week. That’s not a typo. Six. Plus, another 13 amended S-1/A were filed. The total number of SPACs...
At the SPAC of Dawn As we close out Passover and head into Easter weekend, we’re reminded that even the most hopeless situations, like wandering the desert for 40 years, being dead for three days, or trying to close a DeSPAC with zero redemptions in this market, can eventually turn around. After all, SPACs have...
Globa Terra Acquisition Corporation (NASDAQ:GTERU) has filed for a $152.2 million SPAC to find an agriculture or food-tech target company The new SPAC is overfunded to 100.5% and is set to have both a 3/4 warrant and right to a 1/20 share in each of its units. This vies for the most investor-friendly unit coverage of...
EGH Acquisition Corp. (NASDAQ:EGHAU) has filed for a $150 million SPAC to continue the work of the Tortoise serial SPAC team under a fresh name. The new SPAC is not overfunded and will have one right to a 1/10 share in each of its units. It will have 24 months to initially close a business...
Yorkville Acquisition Corp. has filed for a $150 million SPAC to bring the sponsor’s experience in SPAC investing to a search for a technology, media or telecom target. The new SPAC is overfunded to 100.5% with $10.05 per unit in trust initially. Each unit is set to contain a 1/3 share and it will have...